Health-care shares were flat to higher in pre-market trade
In health-care-stocks news, biopharmaceutical company Alexion
) raised its outlook for net product sales and non-GAAP earnings
for 2014 to account for increased revenue related to an agreement
concluding discussions with the French government regarding the
prospective reimbursement of Soliris.
ALXN was up 3.4% in recent
, in a 52-week range of $87.01 to $185.43.
Analysts at Oppenheimer downgraded their rating of athenahealth,
) to underperform from perform. The price target on the shares in
the business-services company has been set at $140 a share. In
pre-market activity, shares of ATHN were down 2.7% to $180.11 with
a 52-week range of $82.01 to $206.70.
Also, shares of Regado Biosciences (
) jumped more than 41% pre-market Monday, after the
biopharmaceutical company said the U.S. Food and Drug
Administration has granted its REG1 anticoagulant therapy
fast-track development status. The therapy is designed to be used
in patients with coronary artery disease during percutaneous
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.